Eagle Pharmaceuticals, Inc. is a biotechnology pharmaceutical company, which focuses on developing and commercializing injectable products primarily in the metabolic critical care and oncology areas in the United States. The company is headquartered in Woodcliff Lake, New Jersey and currently employs 134 full-time employees. The company went IPO on 2014-02-12. The firm is focused on developing medicines that result in improvements in patients' lives. The firm's commercialized products include vasopressin, PEMFEXY, RYANODEX, BENDEKA, BELRAPZO, TREAKISYM (Japan), and BYFAVO and BARHEMSYS through its wholly owned subsidiary Acacia Pharma Inc. Its oncology and central nervous system (CNS)/metabolic critical care pipeline includes product candidates with the potential to address underserved therapeutic areas across multiple disease states. The firm also has a research and development facility in Cambridge, Massachusetts. The firm is also focused on developing medicines with the potential to become part of the personalized medicine paradigm in cancer care. The firm has office space in Palm Beach Gardens, Florida and Indianapolis, Indiana.
Follow-Up Questions
Quel est le ratio P/E de Eagle Pharmaceuticals Inc (EGRX) ?
Le ratio P/E de Eagle Pharmaceuticals Inc est de 1.3589
Quelle est la performance du prix de l'action EGRX ?
Le prix actuel de EGRX est de $3.06, il a decreased de 0% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de Eagle Pharmaceuticals Inc ?
Eagle Pharmaceuticals Inc appartient à l'industrie Biotechnology et le secteur est Health Care
Quelle est la capitalisation boursière de Eagle Pharmaceuticals Inc ?
La capitalisation boursière actuelle de Eagle Pharmaceuticals Inc est de $39.7M
Est-ce que Eagle Pharmaceuticals Inc est un achat, une vente ou un maintien ?
Selon les analystes de Wall Street, 3 analystes ont établi des notations d'analystes pour Eagle Pharmaceuticals Inc, y compris 3 achat fort, 3 achat, 1 maintien, 0 vente et 3 vente forte
